U.S. Biopharmaceutical Third Party Logistics Industry Overview
The U.S. biopharmaceutical third party logistics market size was valued at USD 36.4 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2021 to 2028.
The market is majorly driven by the launch of innovative biopharmaceutical products including cell gene therapies that are creating more demand for cold chain storage, transport distribution solutions. Moreover, 3PL service providers are also investing in technology due to fluctuating demand, capacity problems, and ongoing disruptions owing to the COVID-19 pandemic. The pandemic has led to restrictions on air travel disrupting the airfreight market delaying of supply of health products including vaccines to many countries. In the initial months of the pandemic, all the existing airfreight rates were suspended with UNICEF registering rate rises by as much as 500% but stabilizing at between 150 to 250%.
Gather more insights about the market drivers, restrains and growth of the U.S. Biopharmaceutical Third Party Logistics Market
The COVID-19 pandemic has uncovered vulnerabilities within the supply chains, including the risk of just-in-time inventory the likely benefits of relocating production near to the consumption point. A study looked at areas most impacted by the pandemic for shippers that comprises international transportation logistics (43%), sourcing procurement (30%), and manufacturing (24%). The third-party logistics market was largely impacted by labor workforce management (33%), manufacturing (24%), and international transportation logistics (23%).
The pandemic has also enhanced the demand within the cold chain. Maximum shippers expect the demand for cold chain capacity to rise over the next three years. Hence, most third-party providers have speeded up their growth plans, thus increasing their need for more cold chain capacity.
In addition, the companies are also playing a key role in the pandemic to meet the growing demand. For instance, McKesson’s deep expertise in the healthcare supply chain is playing an important role in delivering medical supplies pharmaceuticals to customers patients during critical times. This comprises supporting the U.S. government as a centralized distributor of the COVID-19 vaccines and the ancillary supply kits required to administer them.
Browse through Grand View Research's Medical Devices Industry Research Reports.
- Cold Chain Market - The global cold chain market size was valued at USD 210.49 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 14.8% from 2021 to 2028. The growing penetration of connected devices and automation of refrigerated warehouses across the globe is anticipated to spur the industry growth over the forecast period.
- Workforce Management Market - The global workforce management market size was estimated at USD 6.1 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 10.0% over the forecast period. Factors such as workforce optimization, increasing cloud deployment, and the need to comply with regulatory mandates are responsible for driving the market growth.
U.S. Biopharmaceutical Third Party Logistics Market Segmentation
Grand View Research has segmented the U.S. biopharmaceutical 3PL market on the basis of supply chain, service type, and product type:
U.S. Biopharmaceutical 3PL Supply Chain Outlook (Revenue, USD Billion, 2016 - 2028)
- Cold Chain
- Non-cold Chain
U.S. Biopharmaceutical 3PL Service Type Outlook (Revenue, USD Billion, 2016 - 2028)
- Transportation
- Air Freight
- Sea Freight
- Overland Transportation
- Warehousing Storage
- Others
U.S. Biopharmaceutical 3PL Product Type Outlook (Revenue, USD Billion, 2016 - 2028)
- Specialty Drugs
- Generics
- Plasma-derived Products
- Others
Market Share Insights
- March 2021: FedEx Express announced that it has started shipping the newly approved vaccines for COVID-19 to dosing centers all over the U.S. on behalf of McKesson Corporation.
Key Companies profiled:
Some prominent players in the U.S. biopharmaceutical third party logistics market include
- FedEx.
- DHL International GmbH
- SF Express
- United Parcel Service of America, Inc.
- AmerisourceBergen Corporation
- DB Schenker
- KUEHNE + NAGEL
- Kerry Logistics Network Ltd.
- Agility
Order a free sample PDF of the U.S. Biopharmaceutical Third Party Logistics Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
